Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Running, not enrolling · Phase 2
Conditions studied: Non-Small Cell Lung Cancer
In brief
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Key facts
- Study ID
- NCT03944772
- Run by
- AstraZeneca
- People needed
- 247
- Starts
- 2019-06-25
- Expected to finish
- 2025-05-06
- Last updated by the study team
- 2025-01-30
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Duarte, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — Sacramento, California, United States
- Research Site — Santa Monica, California, United States
- Research Site — New Haven, Connecticut, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Grand Rapids, Michigan, United States
- Research Site — New York, New York, United States
- Research Site — New York, New York, United States
- Research Site — Portland, Oregon, United States
- Research Site — Pittsburgh, Pennsylvania, United States
- Research Site — Houston, Texas, United States
- Research Site — Seattle, Washington, United States
- Research Site — Odense C, Denmark
- Research Site — Catania, Italy
- Research Site — Naples, Italy
- Research Site — Orbassano, Italy
- Research Site — Padova, Italy
- Research Site — Varese, Italy
- Research Site — Chūōku, Japan
- Research Site — Fukuoka, Japan
- Research Site — Kōtoku, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.